Genetical changes and uncontrolled cancer growth, which generate intra-tumor hypoxic areas (used by the innovative hypoxia-responsive drug delivery nanoplatforms [78]), cause HIF-1α overexpression enhancing neo-angiogenesis through VEGF synthesis and therefore favoring cancer progression and metastasis [79]. The gene discussed is HIF1A; the disease is cancer.